Open AccessTwo Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer
Author(s) -
Yoko Fujii-Nishimura,
Ryuichi Nishiyama,
Minoru Kitago,
Yohei Masugi,
Akihisa Ueno,
Koichi Aiura,
Shigeyuki Kawa,
Miho Kawaida,
Yuta Abe,
Masahiro Shinoda,
Osamu Itano,
Akihiro Tanimoto,
Michiie Sakamoto,
Yuko Kitagawa
Publication year - 2015
Publication title -
keio journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.24
H-Index - 43
eISSN - 1880-1293
pISSN - 0022-9717
DOI - 10.2302/kjm.2014-0014-cr
Subject(s) - medicine , pancreatectomy , pancreatic cancer , neoadjuvant therapy , pathological , adenocarcinoma , radiation therapy , pancreatic intraepithelial neoplasia , oncology , cisplatin , pancreatic ductal adenocarcinoma , cancer , radiology , chemotherapy , pancreas , breast cancer
Neoadjuvant chemoradiation therapy (NACRT) is increasingly used in patients with a potentially or borderline resectable pancreatic ductal adenocarcinoma (PDA) and it has been shown to improve survival and reduce locoregional metastatic disease. It is rare for patients with PDA to have a pathological complete response (pCR) to NACRT, but such patients reportedly have a good prognosis. We report the clinicopathological findings of two cases of pCR to NACRT in PDA. Both patients underwent pancreatectomy after NACRT (5-fluorouracil, mitomycin C, cisplatin, and radiation). Neither had residual invasive carcinoma and both showed extensive fibrotic regions with several ducts regarded as having pancreatic intraepithelial neoplasia 3/carcinoma in situ in their post-therapy specimens. It is noteworthy that both patients had a history of a second primary cancer. They both had comparatively good outcomes: one lived for 9 years after the initial pancreatectomy and the other is still alive without recurrence after 2 years.